Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingxuan Xia

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Nature Structural & Molecular Biology|February 21, 2007
Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motilityMingxuan Xia, Hartmut Land
Molecular Cancer Research : MCR|September 10, 2009
Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cellsBaoying Huang, Dayanand Deo, Mingxuan Xia, et al.
IEEE Transactions on Cybernetics|December 10, 2020
Incipient Fault Diagnosis for High-Speed Train Traction Systems via Stacked GeneralizationZehui Mao, Mingxuan Xia, Bin Jiang, et al.
Cell Cycle (Georgetown, Tex.)|June 4, 2008
Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradationMingxuan Xia, Dejan Knezevic, Christian Tovar, et al.
Molecular Cancer|May 5, 2011
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancerChristian Tovar, Brian Higgins, Kenneth Kolinsky, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Parkinson's Disease-vulnerable and -resilient dopamine neurons display opposite responses to excitatory inputLotfi C Hadjas, Grace J Kollman, Lexe Linderhof, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2012
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationBradford Graves, Thelma Thompson, Mingxuan Xia, et al.
Cancer Research|February 13, 2013
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer modelsChristian Tovar, Bradford Graves, Kathryn Packman, et al.
Disease Models & Mechanisms|September 11, 2025
The class A repeats of LRP5 are required for normal development of bone, retinal vasculature and mammary gland in vivoCassandra R Diegel, Megan N Michalski, John L Ubels, et al.
Journal of Medicinal Chemistry|July 19, 2021
Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCLLiqiang Fu, Jing Zhang, Bin Shen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Nature Structural & Molecular Biology|February 21, 2007
Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motilityMingxuan Xia, Hartmut Land
Molecular Cancer Research : MCR|September 10, 2009
Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cellsBaoying Huang, Dayanand Deo, Mingxuan Xia, et al.
IEEE Transactions on Cybernetics|December 10, 2020
Incipient Fault Diagnosis for High-Speed Train Traction Systems via Stacked GeneralizationZehui Mao, Mingxuan Xia, Bin Jiang, et al.
Cell Cycle (Georgetown, Tex.)|June 4, 2008
Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradationMingxuan Xia, Dejan Knezevic, Christian Tovar, et al.
Molecular Cancer|May 5, 2011
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancerChristian Tovar, Brian Higgins, Kenneth Kolinsky, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Parkinson's Disease-vulnerable and -resilient dopamine neurons display opposite responses to excitatory inputLotfi C Hadjas, Grace J Kollman, Lexe Linderhof, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2012
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationBradford Graves, Thelma Thompson, Mingxuan Xia, et al.
Cancer Research|February 13, 2013
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer modelsChristian Tovar, Bradford Graves, Kathryn Packman, et al.
Disease Models & Mechanisms|September 11, 2025
The class A repeats of LRP5 are required for normal development of bone, retinal vasculature and mammary gland in vivoCassandra R Diegel, Megan N Michalski, John L Ubels, et al.
Journal of Medicinal Chemistry|July 19, 2021
Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCLLiqiang Fu, Jing Zhang, Bin Shen, et al.
Pageof 1